GlassScriptPhysician profile
Hyunju Lee
NPI 1629483102
$1,630.38
in general payments reported to CMS, 2019-2025
24 companies · $1,504 in 2025
The $1,504 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $127 · 2025: $1,504.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,504.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,503.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $244.56 | 2019-2025 | Tepezza, Evenity, Repatha |
| Novartis Pharmaceuticals Corporation | $226.39 | 2025 | |
| Novo Nordisk INC | $172.64 | 2025 | Wegovy, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $145.13 | 2025 | Jardiance |
| Lilly USA, LLC | $87.52 | 2025 | Mounjaro, Zepbound |
| Averitas Pharma INC. | $83.99 | 2025 | Qutenza |
| Neurocrine Biosciences, INC. | $73.21 | 2025 | |
| Corcept Therapeutics | $70.33 | 2025 | Korlym |
| Recordati_rare_diseases_inc. | $61.01 | 2025 | Isturisa |
| Xeris Pharmaceuticals, INC. | $58.47 | 2025 | Gvoke Hypopen, Recorlev |
| Insulet Corporation | $56.11 | 2025 | Omnipod |
| Mannkind Corporation | $40.04 | 2025 | |
| Medtronic Minimed, INC. | $35.46 | 2019 | |
| Ibsa Pharma INC. | $35.16 | 2025 | Tirosint, Flector, Licart |
| Madrigal Pharmaceuticals | $33.83 | 2025 | Rezdiffra |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $30.59 | 2019 | |
| Sequel Med Tech, LLC | $27.61 | 2025 | Twiist |
| Ionis Pharmaceuticals, INC. | $25.97 | 2025 | Tryngolza |
| Kyowa Kirin, INC. | $25.54 | 2025 | |
| Janssen Pharmaceuticals, INC | $23.59 | 2019 | |
| Tolmar, INC. | $21.01 | 2025 | Jatenzo |
| Tandem Diabetes Care, INC. | $18.71 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Ascendis Pharma Endocrinology INC | $17.66 | 2025 | Yorvipath |
| Currax Pharmaceuticals LLC | $15.85 | 2025 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hyunju Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.